OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA
1. Date of occurrence of the event: Oct 06, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. …
OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.
1. Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2. Date of occurrence of the event: Sep 28, 2020 3. Names of companies participating …
Announcement of press release of press conference on Sept 28, 2020
1. Date and time that the Company disclose its financial or business information to the public: 8 pm on Sep 28, 2020 2. Location that the Company disclose its financial …
Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: Not …
Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: not applicable …
Company Announcement on Board Resolutions
Please refer to https://www.obipharma.com/2020/09/company-announcement-on-board-resolution/?lang=zh-hant for details.
New Appointment of Compensation Committee Member
Date of occurrence of the change: Sep 28, 2020 Name of the functional committees: Compensation committee Name and resume of the previous position holder: Chung-Ming Chang Honorary Research Fellow of …
OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting
Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999. TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid …
TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not …
TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858
1.Date of occurrence of the event: Aug 25, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not …